Jun 2026 (Q2 FY26) — Aug 13, 2026
Kyntra Bio Q2 FY26 — Clinical Programs Advance with Key Catalysts Approaching
Read the full callKyntra Bio (KYNB) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Kyntra Bio earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | -1.5 | −209.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 1192.3 | +2086.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 12.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$5.28 +8.87% · +$0.43
Performance −49.1% 1Y
1Y: $10.38 on 17 Oct 2025 → $5.28. High $11.18 (22 Oct 2025), low $4.85 (16 Oct 2026).
- Previous close
- $4.85
- 52-week range
- $4.85 – $11.18
- One year
- −52.60%
Overview
- Symbol
- KYNB
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Kyntra Bio earnings calls (KYNB)
Financials
What the filings say
Net profit, year on year: +257% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 3 | 3 | 1 | 1 | 1 | 4 | -1 |
| Expenses | 48 | -32 | 18 | 13 | 6 | 15 | 18 | 16 |
| Operating profit | -48 | -92 | -15 | -12 | -5 | -14 | -14 | -18 |
| Operating margin | −38774.0% | −2922.7% | −544.7% | −894.1% | −502.9% | −1058.1% | −369.7% | 1192.3% |
| Other income | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Interest | 2 | -7 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | -48 | -85 | -17 | -14 | -13 | -15 | -15 | 12 |
| Tax rate | −0.0% | 0.1% | −0.0% | 0.7% | 0.0% | 0.0% | 0.0% | −0.0% |
| Net profit | -17 | 18 | 5 | -8 | 201 | -14 | -15 | 12 |
| EPS ($ per share) | -4.25 | — | 1.15 | -1.88 | 49.61 | — | -3.76 | 2.96 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | -716 | -785 | -974 | -1,264 | -1,558 | -1,842 | -1,889 | -1,706 |
| Total liabilities | 352 | 322 | 385 | 545 | 612 | 586 | 398 | 115 |
| Fixed assets | 127 | 43 | 34 | 28 | 21 | 5 | 0 | — |
| Investments | 532 | 407 | 8 | 234 | 266 | 122 | 0 | 41 |
| Total assets | 881 | 857 | 827 | 774 | 610 | 424 | 215 | 120 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -76 | -79 | 82 | -82 | -146 | -315 | -138 | -5 |
| Cash from investing | -522 | 120 | 452 | -427 | 89 | 154 | 126 | 35 |
| Cash from financing | 14 | -4 | 13 | -1 | 47 | 123 | -0 | -86 |
| Net cash flow | -584 | 37 | 552 | -507 | -16 | -42 | -12 | -54 |
| Capital expenditure | -8 | -6 | -4 | -5 | -4 | -3 | -0 | -0 |
| Free cash flow | -84 | -84 | 78 | -87 | -150 | -318 | -138 | -5 |
Insider filings
11 filings between Nov 13, 2025 and Sep 6, 2026.
Open market
decisions to buy or sellPurchases
$53.6K
3 purchases by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 8
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Wettig Thane | $53.6K | — | May 14, 2026 |
Latest filings (34)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 6, 2026 | DeLucia David Chief Financial Officer | Tax withheld | 22 | $188 |
| Sep 6, 2026 | Wettig Thane CEO | Tax withheld | 209 | $1.8K |
| Jun 6, 2026 | Wettig Thane CEO | Tax withheld | 198 | $1.3K |
| Jun 6, 2026 | DeLucia David Chief Financial Officer | Tax withheld | 52 | $349 |
| May 14, 2026 | Wettig Thane CEO | Purchase | 2,800 | $19.9K |
| Mar 6, 2026 | DeLucia David Chief Financial Officer | Tax withheld | 60 | $410 |
| Mar 6, 2026 | Wettig Thane CEO | Tax withheld | 277 | $1.9K |
| Dec 6, 2025 | Wettig Thane CEO | Tax withheld | 259 | $2.2K |
| Dec 6, 2025 | DeLucia David Chief Financial Officer | Tax withheld | 52 | $438 |
| Nov 17, 2025 | Wettig Thane CEO | Purchase | 2,700 | $24.6K |
| Nov 13, 2025 | Wettig Thane CEO | Purchase | 1,000 | $9.2K |
| Sep 6, 2025 | Wettig Thane CEO | Tax withheld | 248 | $3.0K |
| Sep 6, 2025 | DeLucia David Chief Financial Officer | Tax withheld | 53 | $641 |
| Jun 30, 2025 | Schoeneck James A Director | Purchase | 23,567 | $119.5K |
| Jun 6, 2025 | DeLucia David Chief Financial Officer | Tax withheld | 51 | $399 |
| Jun 6, 2025 | Wettig Thane CEO | Tax withheld | 246 | $1.9K |
| Mar 24, 2025 | Wettig Thane CEO | Purchase | 145,000 | $50.7K |
| Mar 21, 2025 | Schoeneck James A Director | Purchase | 50,000 | $17.0K |
| Mar 20, 2025 | Schoeneck James A Director | Purchase | 250,000 | $88.0K |
| Mar 6, 2025 | Chung Christine SVP, CHINA OPERATIONS | Award | 781 | $0 |
| Mar 6, 2025 | Chung Christine SVP, CHINA OPERATIONS | Tax withheld | 422 | $165 |
| Mar 6, 2025 | Wettig Thane CEO | Tax withheld | 22,038 | $8.6K |
| Mar 6, 2025 | Wettig Thane CEO | Award | 781 | $0 |
| Mar 6, 2025 | Wettig Thane CEO | Tax withheld | 367 | $143 |
| Mar 6, 2025 | Chung Christine SVP, CHINA OPERATIONS | Tax withheld | 7,008 | $2.7K |
| Mar 6, 2025 | DeLucia David Chief Financial Officer | Tax withheld | 2,325 | $907 |
| Dec 7, 2024 | Graham Juan CHIEF FINANCIAL OFFICER | Tax withheld | 1,066 | $365 |
| Dec 6, 2024 | Wettig Thane CEO | Tax withheld | 2,363 | $808 |
| Dec 6, 2024 | Chung Christine SVP, CHINA OPERATIONS | Tax withheld | 2,792 | $955 |
| Dec 6, 2024 | Graham Juan CHIEF FINANCIAL OFFICER | Tax withheld | 1,446 | $495 |
| Sep 7, 2024 | Graham Juan CHIEF FINANCIAL OFFICER | Tax withheld | 1,065 | $415 |
| Sep 6, 2024 | Graham Juan CHIEF FINANCIAL OFFICER | Tax withheld | 16,050 | $6.3K |
| Sep 6, 2024 | Chung Christine SVP, CHINA OPERATIONS | Tax withheld | 17,395 | $6.8K |
| Sep 6, 2024 | Wettig Thane CEO | Tax withheld | 2,363 | $922 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for KYNTRA BIO, INC.
Free account. Everything above stays public.
Write why you follow KYNTRA BIO, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading